// App-Quantinova.ai

5178 : Determinants of response to temozolomide in an exceptionally sensitive patient derived model

Researchers

Presenter

  • Lara H. el Touny

Principal Investigators

  • Curtis Hose

  • Anne Monks

  • Mark W. Burkett

  • Erik Harris

  • Rene M. Delosh

  • Julie Laudeman

  • Chad Ogle

  • Russell Reinhart

  • Michael Selby

  • Thomas Silvers

  • David Evans

  • Dianne Newton

  • Luke Stockwin

  • Melinda Hollingshead

  • Ralph Parchment

  • James H. Doroshow

  • Beverly Teicher

  • Annamaria Rapisarda

Medical Centers

  • NCI-Frederick/Leidos Biomed. Research, Inc., Frederick, MD.

  • SAIC-Frederick, Frederick, MD

  • CCR, NIH, Bethesda, MD

  • NCI, Rockville, MD

Locations

  • United States

Companies

  • Leidos Biomedical Re

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Bladder Cancer

  • Lung Cancer

  • Solid malignancies

  • Gliomas

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • O-6-methylguanine DNA methyltransferase

  • Poly(ADP-Ribose) Polymerase 1

  • Histone H2AX

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Temozolomide

  • Carboplatin

  • dacarbazine Intravenous

  • Everolimus

  • Trametinib

  • Veliparib

  • Methadone hydrochloride

  • AZD-1775

  • AS-48

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved